A condom apparatus including at least one of a condom containing a compound of Formula 1 ##STR00001##
wherein the condom is configured to deliver one or more active ingredients selected from the group consisting of arginine, a vasodilator, nitrates, an ergot alkaloid, a long acting alpha-adrenoceptor blocker, a short acting alpha-adrenoceptor blocker, an anti-hypertensive, a prostaglandin, and a phosphodiesterase inhibitor is disclosed.

The present application provides a radiation damage protecting agent comprising hydrogen gas as an active ingredient at a concentration of 18.5% by volume or less, for treating or alleviating, in a hyperbaric capsule under a pressure higher than standard atmospheric pressure, radiation damage in a human patient who has been exposed to radiation or who has received or receives radiotherapy, and a hyperbaric capsule for administering a hydrogen gas-containing therapeutic agent such as the radiation damage protecting agent to a patient including a human.

The present application provides a radiation damage protecting agent comprising hydrogen gas as an active ingredient at a concentration of 18.5% by volume or less, for treating or alleviating, in a hyperbaric capsule under a pressure higher than standard atmospheric pressure, radiation damage in a human patient who has been exposed to radiation or who has received or receives radiotherapy, and a hyperbaric capsule for administering a hydrogen gas-containing therapeutic agent such as the radiation damage protecting agent to a patient including a human.

A method of treating a human subject which is effected by inhalation of gaseous nitric oxide, the method comprising a first treatment period comprising administering gNO by inhalation over a period of about at least 5 days, wherein the first treatment period is followed by a second treatment period comprising administering gNO by inhalation over a period of at least 3 months. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract.

A method of treating a human subject which is effected by inhalation of gaseous nitric oxide, the method comprising a first treatment period comprising administering gNO by inhalation over a period of about at least 5 days, wherein the first treatment period is followed by a second treatment period comprising administering gNO by inhalation over a period of at least 3 months. The method can be utilized for treating a human subject suffering from, or prone to suffer from, a disease or disorder that is manifested in the respiratory tract, or from a disease or disorder that can be treated via the respiratory tract.

A method for preventing or treating an arrhythmia including administering an effective amount of hydrogen to a patient in need thereof.

A method for preventing or treating an arrhythmia including administering an effective amount of hydrogen to a patient in need thereof.

Provided herein are stable aqueous pharmaceutical compositions comprising high concentration formulations of a bispecific epidermal growth factor receptor (EGFR)/hepatocyte growth factor receptor (c-Met) antibody and methods of preparing the same. Also provided herein are methods of treating cancer in a subject in need thereof by subcutaneously administering to the subject the stable aqueous pharmaceutical compositions as disclosed herein.

Methods for disinfecting a surface are provided which include contacting a surface with a solution comprising Fe(VI)O.sub.4.sup.2−, thereby disinfecting the surfaces. In some cases, the surface to be contacted with the solution is in a space suitable for human occupancy and the surface is arranged in the ambient of the space. In addition, solutions comprising Fe(VI)O.sub.4.sup.2− are provided. The solutions may additionally include a hypohalite salt and a surfactant.

Methods for disinfecting a surface are provided which include contacting a surface with a solution comprising Fe(VI)O.sub.4.sup.2−, thereby disinfecting the surfaces. In some cases, the surface to be contacted with the solution is in a space suitable for human occupancy and the surface is arranged in the ambient of the space. In addition, solutions comprising Fe(VI)O.sub.4.sup.2− are provided. The solutions may additionally include a hypohalite salt and a surfactant.